Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 63008G203 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Tang Capital Management LLC
13G
|
9.1% |
8/21/2026
Event 8/19/2026
|
||
| Tang Capital Management, LLC | 9.1% | |||
| Kevin Tang | 9.1% | |||
| Tang Capital Partners, LP | 2.1% | |||
| Tang Capital Partners International, LP | 2.8% | |||
| Tang Capital Partners III, Inc | 2.1% | |||
| Tang Capital Partners IV, Inc | 2.1% | |||
|
Murchinson Ltd.
13D/A
|
8.1% |
7/20/2026
Event 7/17/2026
|
||
| Murchinson Ltd. | 8.1% | |||
| Nomis Bay Ltd. | 2.4% | |||
| BPY Ltd. | 1.6% | |||
| EOM Management Ltd. | 4.1% | |||
| James Keyes | 4.1% | |||
| Jason Jagessar | 4.1% | |||
| Chaja Carlebach | 4.1% | |||
| Clarendon Hugh Masters | 4.1% | |||
| Marc J. Bistricer | 8.1% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
|
Anson Funds Management LP
13D/A
|
4.2% |
7/14/2025
Event 7/11/2025
|
||
| Anson Funds Management LP | 4.2% | |||
| Anson Management GP LLC | 4.2% | |||
| Tony Moore | 4.2% | |||
| Anson Advisors Inc. | 4.2% | |||
| Amin Nathoo | 4.2% | |||
| Moez Kassam | 4.2% | |||
| Oramed Pharmaceuticals Inc. 13D/A | 3.3% |
7/22/2026
Event 7/20/2026
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 8 | 84.2 k | $132 k |
| 2026 Q2 | 113 | 67.2 M | $97.4 M |
| 2026 Q1 | 114 | 59.1 M | $100 M |
| 2025 Q4 | 126 | 70.0 M | $108 M |
| 2025 Q3 | 129 | 71.8 M | $113 M |
| 2025 Q2 | 140 | 77.5 M | $126 M |
| 2025 Q1 | 153 | 74.3 M | $118 M |
| 2024 Q4 | 160 | 76.9 M | $191 M |
| 2024 Q3 | 151 | 70.8 M | $173 M |
| 2024 Q2 | 144 | 74.0 M | $163 M |
| 2024 Q1 | 142 | 76.7 M | $213 M |
| 2023 Q4 | 153 | 73.2 M | $176 M |
| 2023 Q3 | 150 | 69.7 M | $189 M |
| 2023 Q2 | 150 | 74.7 M | $216 M |
| 2023 Q1 | 155 | 89.1 M | $257 M |
| 2022 Q4 | 166 | 71.7 M | $1.09 B |
| 2022 Q3 | 170 | 60.7 M | $145 M |
| 2022 Q2 | 172 | 64.9 M | $201 M |
| 2022 Q1 | 179 | 57.6 M | $205 M |
| 2021 Q4 | 181 | 54.4 M | $208 M |
| 2021 Q3 | 173 | 47.9 M | $271 M |
| 2021 Q2 | 185 | 52.3 M | $431 M |
| 2021 Q1 | 170 | 43.2 M | $370 M |
| 2020 Q4 | 117 | 25.4 M | $232 M |
| 2020 Q3 | 36 | 1.47 M | $4.21 M |
| 2020 Q2 | 31 | 1.28 M | $2.81 M |
| 2020 Q1 | 12 | 365 k | $349 k |
| 2019 Q4 | 11 | 110 k | $281 k |
| 2019 Q3 | 2 | 743 k | $305 k |
| 2019 Q2 | 1 | 800 | $7.00 k |
| 2019 Q1 | 1 | 800 | $7.00 k |